• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 6
  • 2
  • 1
  • Tagged with
  • 9
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
1

Substituted 4H-1,2,4-Triazoles with antihypertensive properties synthesis and structure-activity relationships /

Emilsson, Håkan. January 1983 (has links)
Thesis (doctoral)--Uppsala, 1983.
2

Hemodynamic effects of antihypertensive drugs in conscious spontaneously hypertensive rats

Nievelstein, Hubert Nicolas Maria Willem. January 1987 (has links)
Proefschrift Maastricht. / Lit.opg. - Met samenvatting in het Nederlands.
3

Antihypertensive drugs and the microcirculation

Messing, Marcellinus Wilhelmus Johannes. January 1992 (has links)
Proefschrift Maastricht. / Met lit. opg. - Met samenvatting in het Nederlands.
4

Exercise and cardiovascular risk reduction

Wijnen, Joseph Anna Guillaume. January 1994 (has links)
Proefschrift Rijksuniversiteit Maastricht. / Met lit. opg. - Met een samenvatting in het Nederlands.
5

Hur påverkar olika NSAIDs antihypertensiva läkemedel?

Sundell, Alexandra January 2011 (has links)
Det finns många läkemedel som höjer blodtrycket eller interagerar med antihypertensiva läkemedel vilket motverkar en blodtryckssänkning. Den vanligaste interaktionen är en försämring av de antihypertensiva läkemedlens effekt på grund av intag av non steroidal anti-inflammatory drugs, NSAIDs (7). Syftet med denna litteraturstudie är att försöka besvara: Hur påverkas olika grupper av antihypertensiva läkemedel? Hur påverkar traditionella NSAID preparat respektive COX-2 hämmare effekten av antihypertensiva läkemedel? Hur allvarliga är interaktionerna? Vilken dos behövs för att en interaktion mellan NSAIDs och antihypertensiva läkemedel ska uppstå? Vilka typer av patienter utgör riskgrupper? Nio randomiserade kontrollerade kliniska studier inkluderades i detta examensarbete. Studierna undersökte sju olika NSAIDs; diklofenak, ibuprofen, indometacin, piroxikam, sulindac, celecoxib och rofecoxib, och representerade flertalet olika typer av antihypertensiva läkemedelsbehandlingar. Ingen signifikant påverkan på blodtrycket sågs då NSAIDs kombinerades med kalciumantagonister. En signifikant ökning av blodtrycket sågs för ACE-hämmare, ARBs, betablockare och diuretika. Ingen av studierna visade någon signifikant skillnad på interaktionskänslighet mellan ACE-hämmare, ARBs, betablockare eller diuretika. Blodtrycksökningar sågs för diklofenak, ibuprofen, indometacin, piroxikam, och rofecoxib. Celecoxib undersöktes i tre studier och påverkade inte blodtrycket i någon av dem. Slutsatser: Den individuella kardiovaskulära risken för olika NSAIDs beror på flera olika faktorer förutom COX-2 specificitet. Risken är svårbedömd och ännu kan inga NSAIDs klassas som säkra vad gäller kardiovaskulär risk. Dock tycks celecoxib sakna blodtryckhöjande effekter och skulle kunna vara ett bra alternativ för de hypertoniker som behöver samtidig behandling med NSAID preparat. Trots detta kan inga slutsatser dras om celecoxibs kardiovaskulära risk då preparatet skulle kunna påverka andra riskfaktorer förutom blodtryck. Interaktionsmekanismen mellan NSAIDs och antihypertensiva läkemedel är fortfarande oklar och fler studier på detta område behövs. Men troliga teorier är att NSAIDs hämning prostaglandinsyntesen ger en ökad perifer resistens samt en ökad volymretention. Båda dessa effekter ger ett ökat blodtryck. Interaktionen ger relativt små blodtrycksökningar men dessa är kliniskt relevanta då de kvarstår en längre tid. Hos hypertonipatienter där samtidig behandling med NSAIDs är nödvändigt bör blodtrycket och njurfunktion stå under noggrann övervakning.
6

Interaktioner vid behandling med antihypertensiva läkemedel : En litteraturstudie om förekomst av interaktioner hos patienter som behandlas för hypertoni / Interactions during treatment with antihypertensive drugs : A literature review on the incidence of interactions in patients treated for hypertension

Holmqvist, Matilda January 2021 (has links)
Hypertension is defined as a systolic blood pressure of ≥140 mmHg and/or a diastolic blood pressure of  ≥90 mmHg. The incidence in the Swedish population is 27%. Hypertension becomes one of the leading causes of morbidity and mortality as it increases the risk of developing cardiovascular disease. The cause of hypertension isn’t known yet, but risk factors such as age and obesity have been identified. Hypertension is treated by lifestyle change or by pharmacological treatment. Angiotensen converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers and thiazide diuretics are the different drugs that are primarily used for treating of hypertension. The most common definition of polypharmacy is  the use of five or more drugs within the same period of time and it’ss associated with an increased risk of interactions and side effects.  Patients with hypertension are characterized by old age, polypharmacy and increased number of hospital stays, making them particularly vulnerable to drug interactions. The blood pressure can be affected by drug-drug interactions between antihypertensive drugs and other medications may increase or decrease the lowering effect of the blood pressure.  The aim of this literature study is to evaluate the common interactions that may occur during treatment with antihypertensive drugs, and the prevalence of these interactions. Five studies were retrieved from the PubMed database and were then analyzed.  The prevalence of drug-drug interactions in each study was 48%, 71.5%, 21.14%, 90.6% and 83.42%. The majority of patients were between 40 and 60 years old and the number of prescriptions per patient was around 5. The results of this literature study show that the prevalence of potential drug interactions is high and that interactions involving atenolol, metoprolol, amlodipine, NSAIDs and insulin are commonly occurring. The results also show that polypharmacy, age and comorbidity significantly increases the risk of drug-drug interactions. / Hypertoni definieras som ett systoliskt tryck som är ≥140 mmHg och/eller ett diastoliskt tryck som är ≥90 mmHg. Förekomsten i Sverige är cirka 27 %. Hypertoni utgör en av de främsta orsakerna till sjuklighet och dödlighet då det innebär en kraftig förhöjd risk att drabbas av kardiovaskulära sjukdomar. Orsaken till hypertoni är ännu inte känd, men riskfaktorer som hög ålder och övervikt har identifierats. Behandling av hypertoni sker genom livsstilsförändringar eller farmakologisk behandling. Angiotensin converting enzyme (ACE)-hämmare, angiotensin-receptorblockerare (ARB), kalciumantagonister och tiaziddiuretika används i första hand. Den vanligaste defintionen av polyfarmaci är  att en patient behandlas med fem eller fler läkemedel samtidigt och detta innebär en ökad risk för interaktioner och biverkningar. Patienter med hypertoni kännetecknas av hög ålder, polyfarmaci och ökad sjukhusvistelse, vilket gör att de är särskilt utsatta för läkemedelsinteraktioner. Kontrollering av blodtrycket kan påverkas genom läkemedelsinteraktioner mellan antihypertensiva läkemedel och andra läkemedel, men också vid samtidig behandling med läkemedel som höjer blodtrycket. Interaktioner mellan antihypertensiva läkemedel och andra läkemedel kan innebära en ökning eller minskning av den blodtryckssänkande effekten. Syftet med denna litteraturstudie är att undersöka vilka vanliga interaktioner som kan förekomma vid behandling med antihypertensiva läkemedel, samt vad prevalensen är för dessa interaktioner. Sju studier hämtades från databasen PubMed och analyserades. Prevalensen av läkemedelsinteraktioner i respektive studie var 48%, 71,5%, 21,14%, 90,6%, 83,42% 55% till 84%, samt 74%.  Majoriteten av patienterna var mellan 40 och 60 år och antalet förskrivna läkemedel per patient var runt 5. Resultatet från den här litteraturstudien visar att prevalensen att potentiellt drabbas av en läkemedelsinteraktion är hög och att interaktioner involverande atenolol, metoprolol, amlodipin, NSAID och insulin är vanligt förekommande. Resultat visar också att polyfarmaci, hög ålder och komborditet signifikant ökar risken att drabbas av läkemedelsinteraktioner.
7

Patterns of antihypertensive drug utilization in primary care

Pittrow, David, Kirch, Wilhelm, Bramlage, Peter, Lehnert, Hendrik, Höfler, Michael, Unger, Thomas, Sharma, Arya M., Wittchen, Hans-Ulrich 21 February 2013 (has links) (PDF)
Background: In the treatment of hypertension, physicians’ attitudes and practice patterns are receiving increased attention as contributors to poor blood pressure (BP) control. Thus, current use of antihypertensive drugs in primary care was analyzed and the association with selected physician and patient characteristics was assessed. Methods: The Hypertension and Diabetes Risk Screening and Awareness (HYDRA) study is a cross-sectional point prevalence study of 45,125 primary care attendees recruited from a representative nationwide sample of 1912 primary care practices in Germany. Prescription frequencies of the various antihypertensive drugs in the individual patients were recorded by the physicians using standardized questionnaires. We assessed the association of patient variables [age, gender; co-morbidities such as diabetes, nephropathy or coronary heart disease (CHD)] and physician variables (general practitioner vs internist, guideline adherence, etc.) with drug treatment intensity and prescription patterns. Results: Of all 43,549 patients for whom a physician diagnosis on hypertension or diabetes was available, 17,485 (40.1%) had hypertension. Of these hypertensive patients, 1647 (9.4%) received no treatment at all, 1191 (6.8%) received non-pharmacological measures only, and 14,647 (83.8%) were given one or more antihypertensive drugs. Drug treatment rates were lower in young patients (16–40 years: 57.4%). BP control was poor: 70.6% of all patients were not normalized, i.e., had BP ≥140/90 mmHg. Antihypertensive treatment was generally intensified with increasing age, or if complications or comorbidities were present. The use of the different drug classes was rather uniform across the various patient subgroups (e.g., by age and gender). Individualized treatment with regard to co-morbidities as recommended in guidelines was not the rule. Adherence to guidelines as self-reported by physicians as well as other physician characteristics (region, training etc.) did not result in more differentiated prescription pattern. Conclusions: Despite the broad armamentarium of drug treatment options, physicians in primary care did not treat hypertension aggressively enough. Treatment was only intensified at a late stage, after complications had occurred. Treatment should be more differentiated in terms of coexisting morbidities such as diabetes, nephropathy, or CHD.
8

Patterns of antihypertensive drug utilization in primary care

Pittrow, David, Kirch, Wilhelm, Bramlage, Peter, Lehnert, Hendrik, Höfler, Michael, Unger, Thomas, Sharma, Arya M., Wittchen, Hans-Ulrich January 2004 (has links)
Background: In the treatment of hypertension, physicians’ attitudes and practice patterns are receiving increased attention as contributors to poor blood pressure (BP) control. Thus, current use of antihypertensive drugs in primary care was analyzed and the association with selected physician and patient characteristics was assessed. Methods: The Hypertension and Diabetes Risk Screening and Awareness (HYDRA) study is a cross-sectional point prevalence study of 45,125 primary care attendees recruited from a representative nationwide sample of 1912 primary care practices in Germany. Prescription frequencies of the various antihypertensive drugs in the individual patients were recorded by the physicians using standardized questionnaires. We assessed the association of patient variables [age, gender; co-morbidities such as diabetes, nephropathy or coronary heart disease (CHD)] and physician variables (general practitioner vs internist, guideline adherence, etc.) with drug treatment intensity and prescription patterns. Results: Of all 43,549 patients for whom a physician diagnosis on hypertension or diabetes was available, 17,485 (40.1%) had hypertension. Of these hypertensive patients, 1647 (9.4%) received no treatment at all, 1191 (6.8%) received non-pharmacological measures only, and 14,647 (83.8%) were given one or more antihypertensive drugs. Drug treatment rates were lower in young patients (16–40 years: 57.4%). BP control was poor: 70.6% of all patients were not normalized, i.e., had BP ≥140/90 mmHg. Antihypertensive treatment was generally intensified with increasing age, or if complications or comorbidities were present. The use of the different drug classes was rather uniform across the various patient subgroups (e.g., by age and gender). Individualized treatment with regard to co-morbidities as recommended in guidelines was not the rule. Adherence to guidelines as self-reported by physicians as well as other physician characteristics (region, training etc.) did not result in more differentiated prescription pattern. Conclusions: Despite the broad armamentarium of drug treatment options, physicians in primary care did not treat hypertension aggressively enough. Treatment was only intensified at a late stage, after complications had occurred. Treatment should be more differentiated in terms of coexisting morbidities such as diabetes, nephropathy, or CHD.
9

Telemetrisch kontrollierte Blutdrucktherapie bei Patienten mit unzureichend eingestelltem Hypertonus / Telemetric monitoring of blood pressure treatment in patients with inadequately treated hypertension

Neumann, Claas Lennart 15 September 2010 (has links)
No description available.

Page generated in 0.0813 seconds